NervGen Pharma Corp.

NervGen announced the appointment of Randall Kaye, MD, to the role of Chief Medical Advisor. Dr. Kaye will expand his capacity as a member of NervGen’s Board of Directors and Chair of the Science Committee to medical advisor to the company. Read the full release: https://lnkd.in/gsrfe8KE #announcement #SCI #spinalcordinjury

“We achieved our primary endpoint demonstrating improved hand-motor connectivity and showed positive improvement in hand function in the chronic cohort of our Phase 1b/2a trial,” said Michael Kelly, NervGen’s President and Chief Executive Officer. Chief Medical Officer, Daniel Mikol MD, PhD, will present the positive study results in-person today at the @ASIA_spine 2025 Annual Scientific Meeting. Learn more: https://lnkd.in/etWNgNXq #SCI #clinicaltrial #ASIA2025 #ASIA2025SCIAnnualMeeting

Today, NervGen announced the results from the chronic cohort (1-10 years post-injury) of its Phase 1b/2a clinical trial evaluating its lead drug candidate, NVG-291, in spinal cord injury.     Read more about the results: https://lnkd.in/etWNgNXq      #announcement #trialresults #SCI #innovation 

At NervGen, the clinical trial for our lead drug candidate, NVG-291, has a unique design where we study connectivity using electrophysiology in partnership with the Shirley Ryan AbilityLab. Watch to learn more: https://lnkd.in/eQbB-uSZ #spincalcordinjury #science #innovation #clinicaltrial 

Did you know, in the U.S., spinal cord injury (#SCI) affects over 300,000 people and there are currently no approved drugs to enable sustained functional recovery?    At NervGen, we’re working to change that. Our lead drug candidate, NVG-291, is a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair.    Learn more about the science: https://lnkd.in/eXv4D7Bd   #spinalcordinjury #clinicaltrial #science #innovation

On Tuesday, June 3, Chief Medical Officer Daniel Mikol MD, PhD will present at the upcoming AMERICAN SPINAL INJURY ASSOCIATION 2025 Annual Scientific Meeting.    Learn more: https://lnkd.in/eqZeqtSc   #SCI #spinalcordinjury #clinicaltrial #ASIA2025SCIAnnualMeeting #ASIA2025Scottsdale #innovation

“Can you imagine waking up from a coma, being told that you shouldn’t be alive? Oh, and by the way, you’ll never move your legs ever again.” - John Ruffolo, Board Member.    There are approximately 18,000 new spinal cord injury (SCI) cases in the U.S. each year. NervGen is dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease potentially helping those living with #SCI.    Learn more about our technology: https://lnkd.in/eQbB-uSZ   #spinalcordinjury #clinicaltrial #science #innovation

#NEWS: Today, NervGen reported its Q1 2025 financial results and operational updates.     See the full release: https://lnkd.in/evFb-HQF   #earnings #announcement 

NervGen announced the results of its Annual General Meeting of Shareholders that was held on May 6, 2025. Read the full release: https://bit.ly/4jLspXm #Shareholders #announcement #SCI

Our President & CEO Michael Kelly will be discussing our innovative approach and clinical trial in spinal cord injury at the Bloom Burton & Co. Healthcare Investor Conference next month. It’s an important and exciting year for our team at NervGen, and we are looking forward to connecting with partners and investors for one-on-one meetings.  Learn more: https://bit.ly/4d0doOZ #BBHIC2025 #innovation #SCI #SpinalCordInjury #biotech #healthcare